TransCode Therapeutics, Inc. (NASDAQ: RNAZ)
Key Finding: TransCode Therapeutics (RNAZ) is a micro-cap clinical-stage biotech company advancing RNA-targeted therapeutics via its TTX nanoparticle platform, with its lead candidate TTX-MC138 recently completing a successful Phase 1a trial and entering Phase 2a development for metastatic cancers as of mid-2026.
Company Overview
TransCode Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers, particularly metastatic disease.0
- Headquarters: Boston, Massachusetts
- Founded: January 2016
- Employees: 12 (as of 2026)
- Website: transcodetherapeutics.com
- IR Site: ir.transcodetherapeutics.com
- Platform: Proprietary TTX iron oxide nanoparticle delivery system for RNA therapeutics targeting microRNAs and other pathways.
Lead candidate: TTX-MC138 (antagomiR targeting microRNA-10b, a master regulator of metastasis in multiple cancer types including breast, pancreatic, colorectal, and glioblastoma).
Other pipeline: TTX-siPDL1, TTX-RIGA, TTX-siMYC, SEVIPROTIMUT-L (melanoma vaccine, Phase 2 completed), and oncolytic virus therapy.
The company positions itself as addressing unmet needs in metastatic cancer through targeted RNA delivery, a historically challenging area.
Company History
- Incorporated in 2016 by founders including Zdravka Medarova, Anna Moore, and Robert Michael Dudley, building on academic research into microRNA-10b and nanoparticle delivery.
- Developed the TTX platform for delivering oligonucleotides to tumors and metastases.
- Went public via NASDAQ listing (RNAZ).
- November 2024: 1-for-33 reverse stock split effective; secured $8M private placement.
- 2026 developments: Multiple financings, Nasdaq compliance efforts, Phase 1a completion, and Phase 2a initiation.
Exact IPO or listing date not detailed in recent sources; company has undergone significant dilution and reverse splits typical of early-stage biotechs.
Recent News (as of July 2026)
- June 18, 2026: R&D Webcast highlighting TTX-MC138 Phase 2a trial, pipeline, and investment thesis.
- June 3, 2026: Successfully completed Phase 1a trial of TTX-MC138 in metastatic cancer patients; reported safety (no dose-limiting toxicities) and durable disease stabilization; advancing to Phase 2.
- May 27, 2026: Initiated Phase 2a dose-expansion trial with TTX-MC138 in ctDNA-positive colorectal cancer patients (in collaboration with Quantum Leap Healthcare Collaborative).
- April 2026: Appointed Dr. Anna Moore as Chair of Scientific Advisory Board; sponsored research agreement with Michigan State University.
- May 2026: Received Nasdaq listing deficiency notice; adjourned annual meeting amid compliance steps.
- Additional: Flexible financing agreements and share offerings in 2026.
Positive clinical updates in 2026 represent key catalysts, though stock remains highly volatile amid compliance and dilution concerns.
Stock Performance
RNAZ is a micro-cap stock (market cap ~$8-9M) with extreme volatility typical of clinical-stage biotechs.
| Metric | Value (as of ~July 9, 2026) |
|---|
| Recent Close | $7.88 – $9.60 (intraday swings noted) |
| 52-Week Range | $3.82 – $20.99 |
| Market Cap | ~$8-9.2M |
| Volume (recent) | ~35k–66k shares |
| YTD Performance | +41.87% (vs S&P 500 +10.15%) |
| 1-Year Return | +6.19% (approx.) |
Historical Context (approximate annual closes, pre/post-splits adjusted where noted)
| Year | Close (approx.) | Notes |
|---|
| 2026 (YTD) | ~$7.88 | Volatile; recent clinical news drove swings |
| 2025 | ~$6.83 | Significant decline |
| 2024 | ~$94.36 (pre-split adjusted?) | Reverse split impact |
| 2023 | Extremely low post-splits | High dilution history |
Links for more information and live data:
Performance shows high risk/high reward profile driven by clinical milestones and financing events; past returns do not predict future results.
Data Limitations and Assumptions:
- Stock prices, market cap, and performance data are approximate based on sources crawled around July 9, 2026; markets fluctuate rapidly—verify live quotes.
- Clinical trial status reflects company announcements; actual outcomes, regulatory approvals, and commercialization remain uncertain and high-risk for biotech stocks.
- Historical prices heavily impacted by reverse splits (e.g., 2024) and dilutions; adjusted figures may vary.
- No analyst price targets widely reported; micro-cap stocks often lack broad coverage.
- Information synthesized from public web sources; for investment decisions, consult SEC filings, latest 10-Q/10-K, and financial advisors.
Distinction: All statements labeled "fact" are directly supported by company disclosures and financial sites. "Interpretation" reflects analysis of context. "Uncertainty" highlights areas with limited or evolving data.